Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Context Therapeutics Inc.NASDAQ: CNTX
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 18.0% from a year ago
Other current assets stood at $3.99M at the end of Q1 FY2026, up 18.0% from a year earlier and up 69.1% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Other current assets amounted to 6.8% of total assets at the end of Q1 FY2026, up 3.1 pp from a year earlier.
- Other current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +18.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 2.36M USD
- Year-over-year change
- -32.0%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.36M | -32.0% |
| FY2024 | 2024-12-31 | 3.47M | +117.0% |
| FY2023 | 2023-12-31 | 1.6M | -32.2% |
| FY2022 | 2022-12-31 | 2.36M | +79601790540540640.0% |
| FY2021 | 2021-12-31 | (0) | — |
Other Current Assets vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +18.0% is the 5th highest of 10, against a peer median of +4.9%.
- Other current assets amounts to 6.8% of total assets for CNTX, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.37M USD | +4.9% | -4.9% | 3.8% | |
IMAImageneBio Inc | Mar 2026 | $4.7M USD | +59.4% | +303.2% | 3.4% |
| Mar 2026 | $4.62M USD | — | +27406.7% | 2.0% | |
| Mar 2026 | $3.99M USD | +18.0% | +0.0% | 6.8% | |
| Mar 2026 | $3.33M USD | -39.4% | -42.6% | 3.3% | |
| Mar 2026 | €2.91M EUR | -49.1% | +31.1% | 5.9% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $2.51M USD | +61.4% | — | 2.0% |
| Mar 2026 | $2.31M USD | +177.6% | +25.4% | 0.9% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $861K USD | +23.9% | +196.2% | 0.8% |
| Mar 2026 | $244K USD | -89.5% | -63.6% | 1.1% | |
| Dec 2025 | $29K USD | -93.1% | — | 0.1% | |
| Peer median (excluding CNTX) | — | +4.9% | +28.2% | 2.0% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 49.64M | 35.5M | 14.45M | 94.43M | 66M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | (0) | 2.36M | 1.6M | 3.47M | 2.36M |
| Total Current Assets | 51.26M | 37.85M | 16.05M | 97.9M | 68.35M |
| Property, Plant & Equipment (Net) | 0 | 79.54K | 15.52K | 230.78K | 140.07K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 50.39K | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 32.75K | 0 | 0 | 0 |
| Total Non-current Assets | 50.39K | 112.29K | 15.52K | 230.78K | 140.07K |
| Total Assets | 51.31M | 37.97M | 16.06M | 98.13M | 68.49M |
| Account Payables | 1.83M | 936.33K | 2.38M | 1.45M | 2.53M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 85.53K | 853.51K | 661.3K | 941.7K | 1.42M |
| Total Current Liabilities | 3.03M | 3.21M | 4.19M | 2.75M | 8.02M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 0 | 112.06K | 0 |
| Total Liabilities | 3.03M | 3.21M | 4.19M | 2.86M | 8.02M |
| Common Stock | 15.97K | 15.97K | 15.97K | 89.7K | 91.88K |
| Retained Earnings | (29.25M) | (44.09M) | (68.05M) | (94.78M) | (130.9M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 48.27M | 34.76M | 11.87M | 95.27M | 60.47M |
| Total Debt | 0 | 55.08K | 0 | 219.38K | 112.06K |
| Net Debt | (49.64M) | (35.44M) | (14.45M) | (94.21M) | (65.88M) |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.